SPEECH-PROCESSING
10.4.2024 09:03:28 CEST | Business Wire | Press release
Philips Dictation by Speech Processing Solutions, a globally leading innovator in voice technology, has announced the latest innovation in their professional cloud-based dictation and transcription solution, Philips SpeechLive. The enhancement integrates speech recognition from Nuance Dragon. This major development offers the most accurate dictation workflow, leading to new levels of efficiency for legal professionals worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410464123/en/
Philips SpeechLive with Nuance Dragon (Graphic: Business Wire)
Featuring highly precise AI-powered speech recognition integrated directly into legal workflows, this latest version of SpeechLive continuously learns for unmatched accuracy. It empowers time-constrained lawyers to create high-quality documentation while enhancing efficiency and expediting documentation completion. Additionally, assistants can access automated transcripts together with the original recordings for quick corrections, freeing them to concentrate on more meaningful tasks, ultimately boosting work satisfaction and productivity.
Dr. Thomas Brauner, CEO of Speech Processing Solutions, emphasized the significance of this partnership, stating, "The integration of Nuance Dragon into Philips SpeechLive marks a significant enhancement for legal professionals. By merging top-tier AI-powered speech recognition with the best-in-class dictation platform, we're empowering legal professionals to benefit from the best of both worlds. This unique combination will streamline their workflow and achieve new levels of efficiency and accuracy in their document creation process."
Key benefits for legal professionals include:
- Specialized Legal Vocabularies: Access tailored legal vocabularies for precise transcription and industry-specific terminology adherence.
- Custom Profiles: Personalize speech profiles to streamline workflows and boost efficiency, eliminating repetitive corrections.
- Personalized User Recognition: Nuance Dragon's adaptive learning optimizes transcription accuracy, tailoring to individual preferences.
- Enhanced Functionality: Experience streamlined features within SpeechLive, including live dictation and recording capabilities, enhancing workflow efficiency.
- Enhanced Mobility: Access SpeechLive across devices for flexible work arrangements, including PCs and mobile phones, facilitating work from any location.
- Real-time speech recognition with Dragon Bar: Dictate directly into applications for convenience, such as Word documents or Client Management Systems (CMS), simplifying the documentation process.
- Data Security: Philips SpeechLive prioritizes data security, with servers located in five regions worldwide and features such as Multifactor Authentication and Single Sign-on.
In the legal profession, effective communication requires reliance on and integration of precise speech recognition and a seamlessly integrated workflow system.
Philips SpeechLive platform's versatility and convenience cater to the dynamic needs of legal professionals. This all-in-one dictation and transcription platform empowers time-pressed professionals and high-demand firms to save time and earn more money by automating the documentation process between authors and transcriptionists, also allowing them to work flexibly from anywhere.
Free demos of Philips SpeechLive with Nuance Dragon integration are available at www.speechlive.com/dragon-speech-recognition.
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410464123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom